{
    "2021-12-06": [
        [
            {
                "time": "",
                "original_text": "粤开策略深度 | 医药生物行业2022年展望：价值重鸣，创新为锋",
                "features": {
                    "keywords": [
                        "医药生物",
                        "2022年展望",
                        "价值重鸣",
                        "创新为锋"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "九洲药业所持越洋医药股份增至15.19%",
                "features": {
                    "keywords": [
                        "九洲药业",
                        "越洋医药",
                        "持股比例",
                        "15.19%"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}